Tulavi Therapeutics Selected to Exhibit the allay™ Hydrogel Cap at Vizient Innovative Technology Exchange

LOS GATOS, Calif., Aug. 26, 2025 /PRNewswire/ -- Tulavi Therapuetics has been selected to exhibit the allay™ Hydrogel Cap, a first of-its-kind surgical device designed to protect transected nerves and reduce the risk of neuroma formation, at the Vizient® Innovative Technology Exchange. Vizient, the nation's largest provider-driven healthcare performance improvement company, will hold the Exchange Sept. 17 in Las Vegas.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient's hospital clients and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to healthcare delivery or business models.

Each year in the U.S., approximately 600,000 amputations and 1.9M peripheral nerve surgeries are performed. When a peripheral nerve is injured or severed during amputation or surgical soft tissue repair, regenerating axons may grow erratically, leading to the development of symptomatic neuromas. Despite advanced surgical techniques, many patients experience chronic phantom or neuroma pain which can significantly impair mobility, prosthetic use, and overall quality of life.^1,2,3

The allay™ Hydrogel Cap is built on a proprietary hydrogel platform technology that has been safely used in over 5 million patients worldwide and is now engineered specifically to support nerve healing. allay™ is a novel, fully absorbable, and entirely sutureless surgical device that provides a perfectly conforming barrier to the injured nerve, supporting nerve recovery while reducing the risk of symptomatic neuroma formation. Once deployed, the hydrogel cap remains in place for approximately eight months, protecting the nerve and blocking axonal escape during the critical period of neuroma formation.⁴

"It's an honor to be invited to the Vizient Innovative Technology Exchange," said Josh Vose, MD MBA, CEO of Tulavi Therapeutics. "Tulavi's hydrogel-based approach to the surgical care of amputees and those with peripheral nerve injuries is transformative both in application and in addressing the fundamental biology of the injury. We are very excited to demonstrate allay™ and how Tulavi's approach fundamentally improves care."

"The Innovative Technology Exchange fosters a unique opportunity for healthcare providers to interact with products and services that have the potential to impact the healthcare industry and improve clinical care or the business model of organizations," said Kelly Flaharty, senior director of contract services, Vizient. "We are pleased to invite Tulavi Therapeutics to the Exchange."

The annual Innovative Technology Exchange is part of Vizient's Innovative Technology Program that includes product reviews of supplier-submitted technologies by provider-led councils. Since 2003, Vizient has reviewed over 1,700 product submissions as part of its Innovative Technology Program.

About Tulavi Therapeutics
Tulavi Therapeutics, based in Los Gatos, CA, is a privately held medical device company with a mission to redefine peripheral nerve surgery through innovative biomaterial solutions. The company's proprietary in situ forming hydrogel technology represents a breakthrough approach to nerve repair and protection, addressing critical unmet needs in peripheral nerve surgery. Tulavi is committed to advancing patient outcomes and improving the standard of care for surgeons treating peripheral nerve injuries.

Press Contact
Bhavya Dasari
847-778-6367
[email protected]

SOURCE Tulavi Therapeutics, Inc.